Shaji K. Kumar, MD

Dr. Kumar Discusses Advances in the Field of Multiple Myeloma

June 29th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses advances in the field of multiple myeloma.

Dr. Kumar Discusses Daratumumab in Multiple Myeloma

May 18th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab in multiple myeloma.

Dr. Kumar on Studies Investigating Venetoclax in Multiple Myeloma

March 27th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses studies investigating venetoclax (Venclexta) in patients with multiple myeloma.

Dr. Kumar on Next Steps for Venetoclax in Multiple Myeloma

February 10th 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the next steps for venetoclax (Venclexta) in the treatment of patients with multiple myeloma.

Dr. Kumar on the Rationale for Studying Venetoclax in Multiple Myeloma

December 26th 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the rationale for investigating venetoclax as a treatment for patients with multiple myeloma.

Dr. Kumar on Future Treatment Landscape of Multiple Myeloma

November 23rd 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses his vision for the future treatment landscape of multiple myeloma.

Dr. Kumar on the Management of Elderly Patients With Multiple Myeloma

November 10th 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the management of elderly patients with multiple myeloma.

Dr. Shaji Kumar on Novel Frontline Treatment Options in Multiple Myeloma

June 30th 2016

Dr. Kumar on Tourmaline-MM1 Study for Multiple Myeloma

December 6th 2015

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the phase III Tourmaline-MM1 study, which compared the efficacy of the addition of ixazomib to lenalidomide and dexamethasone with lenalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Dr. Kumar on Defining Multiple Myeloma

October 12th 2015

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, gives an overview on the expanded definition of multiple myeloma.

Dr. Kumar on Ixazomib Combo for Multiple Myeloma Treatment

December 24th 2014

Shaji Kumar, MD, professor of medicine at the Mayo Clinic, discusses the use of the proteasome inhibitor ixazomib in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of newly diagnosed multiple myeloma.

Dr. Kumar on the Design of a Phase II Trial of MLN9708

January 15th 2014

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, describes the design of a phase II trial looking at the single-agent activity of the proteasome inhibitor MLN9708 for the treatment of patients with multiple myeloma.

Novel Proteasome Inhibitors for Multiple Myeloma

October 17th 2013

Multiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.

Dr. Kumar on Managing Toxicities in the MLN9708 Study

December 9th 2012

Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, talks about managing toxicities in the MLN9708 study.